Last reviewed · How we verify
BORDETELLA PERTUSSIS TOXIN
Bordetella Pertussis Toxin is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a strong competitive advantage due to its current market presence and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | BORDETELLA PERTUSSIS TOXIN |
|---|---|
| Modality | Vaccine component |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults (PHASE3)
- Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks (NA)
- Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines (PHASE2, PHASE3)
- 5-year Follow-up After a Single Dose Acellular Pertussis Vaccination
- Seroprevalence of Pertussis Among Children and Adolescents in Croatia (NA)
- Viaskin Pertussis Vaccine Trial (PHASE1)
- Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants (PHASE3)
- 2-year Follow-up After a Single Dose Acellular Pertussis Vaccination
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BORDETELLA PERTUSSIS TOXIN CI brief — competitive landscape report
- BORDETELLA PERTUSSIS TOXIN updates RSS · CI watch RSS